As the post-pandemic world of work continues to evolve, so do recruiters’ strategies and tools for finding and engaging top talent. In 2023, we are seeing these seven trends:1. Employer branding is becoming an increasingly important factor in the recruitment…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Debuts Aspirin-PPI Combination Drug Takelda in Japan
June 13, 2014
-
REGULATORY LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
-
BUSINESS Nippon Shinyaku to Concentrate Sales Force in Three Therapeutic Fields
June 11, 2014
-
REGULATORY Ex-Novartis Employee Nabbed over Diovan Data Tampering: Reports
June 11, 2014
-
REGULATORY Govt Tilting Toward Etching Annual NHI Price Revision in Fiscal Blueprint
June 10, 2014
-
ORGANIZATION Generic Versions of Combination Drug Exforge to Be Named “Amvalo”: JSGM
June 10, 2014
-
REGULATORY Researchers Aiming to Craft Guide for Ultra-Orphan Drug Development
June 9, 2014
-
REGULATORY MHLW, Pharma Officials Take to Nagata-cho in Crusade against Yearly NHI Price Revision
June 6, 2014
-
BUSINESS AbbVie Can Achieve 100 Billion Yen Sales Target Ahead of Schedule: President
June 6, 2014
-
REGULATORY MHLW Gets Ball Rolling on OTC Diagnostics Deregulation
June 5, 2014
-
BUSINESS Astellas to Issue Monthly EPPV Reports on Suglat for One Year: Product Manager
June 5, 2014
-
REGULATORY MHLW Should Clear Hurdles, Revise NHI Prices Annually: MOF Budget Examiner
June 4, 2014
-
BUSINESS Teijin Ups FY2015 Japan Sales Target for Feburic to 20-Plus Billion Yen
June 3, 2014
-
REGULATORY Fiscal System Council Renews Call for Annual NHI Price Revision, MHLW Still Guarded
June 2, 2014
-
BUSINESS Daiichi Sankyo to Tout Quick Cardiac Event Reduction for Efient
May 30, 2014
-
REGULATORY Chuikyo to Assess Cost-Effectiveness of 5 Listed Drugs, Industry Leery of Price Cuts
May 29, 2014
-
BUSINESS Novartis to Divest Flu Vaccine Biz within 18 Months
May 28, 2014
-
BUSINESS Taisho Toyama to Center on Safety for Lusefi Promotion: Product Manager
May 27, 2014
-
BUSINESS 3 More SGLT-2 Inhibitors Make Japan Debuts to Trail Suglat
May 26, 2014
-
BUSINESS Blopress AG Rollout Won’t Coincide with June Listing: ASKA Pres.
May 23, 2014
ページ
Novo Nordisk’s weight-loss medication Wegovy (semaglutide) was approved in Japan in March. While it skipped the May round of reimbursement listing, physicians eagerly await the arrival of what would be the first new obesity drug in three decades. Other companies…
Japan’s health ministry on April 27 presented an outline of a report to be compiled next month by its key…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…